Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has submitted an application for a new oral jelly formulation of Aricept in Japan for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
Aricept, an acetylcholinesterase inhibitor developed by Eisai, is claimed to be the only approved prescription medicine for the treatment of Alzheimer’s disease in Japan. It is believed to work by inhibiting the hydrolysis of acetylcholine, thereby increasing available levels of this neurotransmitter in the brain.
In Japan, Aricept is available in tablets, fine granule, and orally rapid disintegrating tablets.